nach oben

Erschienen in:

01.04.2016 | leitlinien für die praxis

Diagnose, Therapie und Verlaufskontrolle der diabetischen Augenerkrankung

verfasst von: Stephan Radda, Matthias Bolz, Stefan Egger, Vanessa Gasser-Steiner, Martina Kralinger, Stefan Mennel, Christoph Scholda, Ulrike Stolba, Andreas Wedrich, Katharina Krepler

Erschienen in: Wiener klinische Wochenschrift | Sonderheft 2/2016

Einloggen, um Zugang zu erhalten

Zusammenfassung

Diabetes mellitus kann diabetische Retinopathie, diabetisches Makulaödem, Optikusneuropathie, Katarakt und Fehlfunktionen der äußeren Augenmuskeln verursachen. Die Inzidenz dieser Spätschäden korreliert mit der Dauer des Diabetes und mit dem Grad der metabolischen Kontrolle. Die Empfehlungen der Österreichischen Diabetesgesellschaft für Diagnose, Therapie und Nachkontrolle werden übersichtsweise und bezogen auf die jeweiligen Stadien der diabetischen Augenerkrankung präsentiert.

Vorheriger Artikel Diabetische Nierenerkrankung – Update 2016

Nächster Artikel Gestationsdiabetes (GDM)

Khadem J, Buzney S, Alich K. Practice patterns in diabetic retinopathy: part 1: analysis of retinopathy follow-up. Arch Ophthalmol. 1999;117:815–20.CrossRefPubMed

McCarty C, Taylor K, McKay R, et al. Diabetic retinopathy: effects of national guidelines on the referral, examination and treatment practices of ophthalmologists and optometrists. Clin Experiment Ophthalmol. 2001;29:52–8.CrossRefPubMed

Wilkinson C, Ferris F, Klein R, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003;110:1677–82.CrossRefPubMed

Hazin R, Colyer M, Lum F, et al. Revisiting Diabetes 2000: challenges in establishing nationwide diabetic retinopathy prevention programs. Am J Ophthalmol. 2011;152:723–9.CrossRefPubMed

Hammes H, Lemmen K Diagnostik, Therapie und Verlaufskontrolle der diabetischen Retinopathie und Makulopathie. Diabetes Stoffwechsel. 2002;11(Suppl 2):15–6.

Klein R, Klein BE, Moss SE. Epidemiology of proliferative diabetic retinopathy. Diabetes Care. 1992;15:1875–91.CrossRefPubMed

Zhang L, Krzentowski G, Albert A, et al. Risk of developing retinopathy in Diabetes Control and Complications Trial type 1 diabetic patients with good or poor metabolic control. Diabetes Care. 2001;24:1275–9.CrossRefPubMed

Stratton I, Kohner E, Aldington S, et al. UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 yrs from diagnosis. Diabetologia. 2001;44:156–63.CrossRefPubMed

Murphy RP, Nanda M, Plotnick L, et al. The relationship of puberty to diabetic retinopathy. Arch Ophthalmol. 1990;108(2):215–8.CrossRefPubMed

10.

Effect of pregnancy on microvascular complications in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. Diabetes Care. 2000;23:1084–91.

11.

Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol. 1998;116:874–86.

12.

Orchard T, Forrest K, Kuller L, et al. Lipid and blood pressure treatment goals for type 1 diabetes: 10-year incidence data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care. 2001;24:1053–9.CrossRefPubMed

13.

Sen K, Misra A, Kumar A, et al. Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. Diabetes Res Clin Pract. 2002;56:1–11.CrossRefPubMed

14.

UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703–13.CrossRefPubMedCentral

15.

Nasr C, Hoogwerf B, Faiman C, et al. United Kingdom Prospective Diabetes Study (UKPDS). Effects of glucose and blood pressure control on complications of type 2 diabetes mellitus. Cleve Clin J Med. 1999;66:247–53.CrossRefPubMed

16.

Davis M, Fisher M, Gangnon R, et al. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: early Treatment Diabetic Retinopathy Study Report Number 18. Invest Ophthalmol Vis Sci. 1998;39:233–52.PubMed

17.

Kinyoun J, Barton F, Fisher M, et al. Detection of diabetic macular edema. Ophthalmoscopy versus photography – Early Treatment Diabetic Retinopathy Study Report Number 5. The ETDRS Research Group. Ophthalmology. 1989;96:746–50.CrossRefPubMed

18.

Gonzalez Villalpando C, Gonzalez Villalpando ME, Martinez Diaz S, et al. A diabetic retinopathy screening program as a strategy for blindness prevention. Arch Med Res. 1997;28:129–35.PubMed

19.

Bolz M, Schmidt-Erfurth U, Deak G, et al. Optical coherence tomographic hyperreflective foci: a morphologic sign of lipid extravasation in diabetic macular edema. Ophthalmology. 2009;116:914–20.CrossRefPubMed

20.

Baskin DE. Optical coherence tomography in diabetic macular edema. Curr Opin Ophthalmol. 2010;21:172–7.CrossRefPubMed

21.

Tangelder GJ, Van der Heijde RG, Polak BC, et al. Precision and reliability of retinal thickness measurements in foveal and extrafoveal areas of healthy and diabetic eyes. Invest Ophthalmol Vis Sci. 2008;49:2627–34.CrossRefPubMed

22.

Browning DJ, Fraser CM. The predictive value of patient and eye characteristics on the course of subclinical diabetic macular edema. Am J Ophthalmol. 2008;145:149–54.CrossRefPubMed

23.

Bolz M, Ritter M, Schneider M, et al. A systematic correlation of angiography and high-resolution optical coherence tomography in diabetic macular edema. Ophthalmology. 2009;116:66–72.CrossRefPubMed

24.

Fluorescein angiographic risk factors for progression of diabetic retinopathy. ETDRS report number 13. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991;98 Suppl 5:834–40.

25.

Pandit RJ, Taylor R. Quality assurance in screening for sight-threatening diabetic retinopathy. Diabet Med. 2002;19:285–91.CrossRefPubMed

26.

Kuo HK, Hsieh HH, Liu RT. Screening for diabetic retinopathy by one-field, non-mydriatic, 45 degrees digital photography is inadequate. Ophthalmologica. 2005;219:292–6.CrossRefPubMed

27.

Case reports to accompany Early Treatment Diabetic Retinopathy Study Reports 3 and 4. The Early Treatment Diabetic Retinopathy Study Research Group. Int Ophthalmol Clin. 1987;27:273–333.

28.

Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991;5:823–33.

29.

Lindgren G, Lindblom B. Causes of vitreous hemorrhage. Curr Opin Ophthalmol. 1996;7:13–9.CrossRefPubMed

30.

Fong D, Ferris F, Davis M, et al. Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Group. Am J Ophthalmol. 1999;127(2):137–41.CrossRefPubMed

31.

Antcliff R, Marshall J. The pathogenesis of edema in diabetic maculopathy. Semin Ophthalmol. 1999;14:223–32.CrossRefPubMed

32.

CDC Diabetes Cost-effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA. 2002;287:2542–51.CrossRef

33.

Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1987;94:761–74.

34.

Kohner E, Stratton I, Aldington S, et al. Relationship between the severity of retinopathy and progression to photocoagulation in patients with Type 2 diabetes mellitus in the UKPDS (UKPDS 52). Diabet Med. 2001;18:178–84.CrossRefPubMed

35.

The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial. Arch Ophthalmol. 1995;113:36–51.

36.

Squirrell D, Bhola R, Bush J, et al. A prospective, case controlled study of the natural history of diabetic retinopathy and maculopathy after uncomplicated phacoemulsification cataract surgery in patients with type 2 diabetes. Br J Ophthalmol. 2002;86:565–71.CrossRefPubMedPubMedCentral

37.

Flesner P, Sander B, Henning V, et al. Cataract surgery on diabetic patients. A prospective evaluation of risk factors and complications. Acta Ophthalmol Scand. 2002;80:19–24.CrossRefPubMed

38.

Chung J, Kim MY, Kim HS, et al. Effect of cataract surgery on the progression of diabetic retinopathy. J Cataract Refract Surg. 2002;28:626–30.CrossRefPubMed

39.

Cunha-Vaz J. Lowering the risk of visual impairment and blindness. Diabet Med. 1998;15(Suppl 4):S47–50.CrossRefPubMed

40.

Aiello LP, Beck RW, Bressler NM, et al. Rationale for the diabetic retinopathy clinical research network treatment protocol for center-involved diabetic macular edema. Ophthalmology. 2011;118:e5–14.CrossRefPubMedPubMedCentral

41.

Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117:1064–77.CrossRefPubMedPubMedCentral

42.

Nguyen QD, Shah SM, Khwaja AA, et al. Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology. 2010;117:2146–51.CrossRefPubMed

43.

Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care. 2010;33:2399–405.CrossRefPubMedPubMedCentral

44.

Elman MJ, Bressler NM, Qin H, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2011;118:609–14.CrossRefPubMedPubMedCentral

45.

Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119:789–801.CrossRefPubMed

46.

Elman MJ, Ayala A, Bressler NM, Browning D, Flaxel CJ, Glassman AR, Jampol LM, Stone TW, Diabetic Retinopathy Clinical Research Network. Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. Ophthalmology. 2015;122:375–81. doi:10.1016/j.ophtha.2014.08.047.CrossRefPubMedPubMedCentral

47.

Korobelnik JF, Do DV, Schmidt-Erfurth U, Boyer DS, Holz FG, Heier JS, Midena E, Kaiser PK, Terasaki H, Marcus DM, Nguyen QD, Jaffe GJ, Slakter JS, Simader C, Soo Y, Schmelter T, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Zeitz O, Metzig C, Brown DM. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014;121(11):2247–54. doi:10.1016/j.ophtha.2014.05.006.CrossRefPubMed

48.

Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, Arnold-Bush B, Baker CW, Bressler NM, Browning DJ, Elman MJ, Ferris FL, Friedman SM, Melia M, Pieramici DJ, Sun JK, Beck RW. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372:1193–203. doi:10.1056/NEJMoa1414264.CrossRef

49.

Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118:615–25.CrossRefPubMed

50.

Boyer DS, Yoon YH, Belfort R Jr, Bandello F, Maturi RK, Augustin AJ, Li XY, Cui H, Hashad Y, Whitcup SM, Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121:1904–14. doi:10.1016/j.ophtha.2014.04.024.CrossRefPubMed

51.

Campochiaro PA, Brown DM, Pearson A, Ciulla T, Boyer D, Holz FG, Tolentino M, Gupta A, Duarte L, Madreperla S, Gonder J, Kapik B, Billman K, Kane FE. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology. 2011;118:626–35.e2. doi:10.1016/j.ophtha.2010.12.028.CrossRefPubMed

52.

Preliminary report on effects of photocoagulation therapy. The Diabetic Retinopathy Study Research Group. Am J Ophthalmol. 1976;81:383–96.

53.

Techniques for scatter and local photocoagulation treatment of diabetic retinopathy: early Treatment Diabetic Retinopathy Study Report no. 3. The Early Treatment Diabetic Retinopathy Study Research Group. Int Ophthalmol Clin. 1987;27:254–64.

54.

Googe J, Brucker AJ, Bressler NM, et al. Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation. Retina. 2011;31:1009–27.CrossRefPubMed

55.

Ferris F. Early photocoagulation in patients with either type I or type II diabetes. Trans Am Ophthalmol Soc. 1996;94:505–37.PubMedPubMedCentral

56.

Bodanowitz S, Hesse L, Weinand F, et al. Vitrectomy in diabetic patients with a blind fellow eye. Acta Ophthalmol Scand. 1996;74:84–8.CrossRefPubMed

57.

Filho JA, Messias A, Almeida FP, et al. Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy. Acta Ophthalmol. 2011;89:567–72.CrossRef

58.

Kohner EM, Barry PJ. Prevention of blindness in diabetic retinopathy. Diabetologia. 1984;26:173–9.CrossRefPubMed

59.

Rand LI, Prud’homme GJ, Ederer F, et al. Factors influencing the development of visual loss in advanced diabetic retinopathy. Diabetic Retinopathy Study (DRS) Report No. 10. Invest Ophthalmol Vis Sci. 1985;26:983–91.PubMed

60.

Dogru M, Nakamura M, Inoue M, et al. Long-term visual outcome in proliferative diabetic retinopathy patients after panretinal photocoagulation. Jpn J Ophthalmol. 1999;43:217–24.CrossRefPubMed

Titel: Diagnose, Therapie und Verlaufskontrolle der diabetischen Augenerkrankung
verfasst von: Stephan Radda
Matthias Bolz
Stefan Egger
Vanessa Gasser-Steiner
Martina Kralinger
Stefan Mennel
Christoph Scholda
Ulrike Stolba
Andreas Wedrich
Katharina Krepler
Publikationsdatum: 01.04.2016
Verlag: Springer Vienna
Erschienen in: Wiener klinische Wochenschrift / Ausgabe Sonderheft 2/2016
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI: https://doi.org/10.1007/s00508-016-0983-z

Springer Medizin Österreich

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 2/2016

Gravidität bei vorbestehendem Diabetes für die Leitlinien für die Praxis (AG Diabetes und Schwangerschaft der ÖDG)

Austrian Lipid Consensus on the management of metabolic lipid disorders to prevent vascular complications

Insulinpumpentherapie bei Kindern, Jugendlichen und Erwachsenen

Diabetes mellitus im Kindes- und Jugendalter

Lipide: Diagnostik und Therapie bei Diabetes mellitus

Psychische Erkrankungen und Diabetes mellitus